QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is EPO (High-Dose)??
This 10,000 IU/vial high-dose formulation of recombinant human erythropoietin (rhEPO) is designed for research protocols requiring elevated EPO concentrations — dose-escalation studies, supraphysiological receptor saturation kinetics, high-burden anaemia models, or multi-arm concentration-response assays. EPO binds the homodimeric EPOR, activating JAK2/STAT5, PI3K/Akt, and MAPK pathways to stimulate red blood cell differentiation, survival, and haemoglobin synthesis. EPOR expression in non-haematopoietic tissues also supports neuroprotection and cardioprotection research.
Research Applications
High-Dose Erythropoiesis
Supraphysiological RBC stimulation, dose-escalation BFU-E/CFU-E models, EPOR saturation kinetics
JAK2/STAT5 Signalling
EPOR kinase cascade profiling at high receptor occupancy
Severe Anaemia Models
High-burden chemotherapy-induced, renal, and haemolytic anaemia preclinical models
Neuroprotection
High-dose EPOR activation in neuronal ischaemia, spinal cord injury, and TBI models
Cardioprotection
Cardiomyocyte EPOR, myocardial infarction protection, high-dose cardiac remodelling studies
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 11096-26-7 |
| Activity | 10,000 IU/vial |
| Molecular Weight | ~30.4 kDa (glycosylated) |
| Peptide Type | Recombinant glycoprotein hormone / haematopoietic growth factor — high dose |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months unopened |
